Thermo Fisher Scientific's first quarter earnings for 2026 went beyond expectations. However, its shares dropped due to extended growth concerns. Its Q1 profit per share was $4.43, outstripping the anticipated $4.17, while the total revenue amassed was $11.01 billion. The company adjusted its full-year guidance in light of the results. Despite inflation risks tied to tensions in Iran, Thermo Fisher raised its outlook based on AI enhancements made through its Clario deal. Described as 'modest inflation', the risk has triggered a weak demand from US academics. The 'soft organic growth and weaker diagnostic/instrument trends' have negatively impacted the company's share price, which at present sits at $466.70, significantly below its GF value of $579.60. Thermo Fisher, however, continued robust performance, marked by new collaborations and product development. The company's shares were bought by other entities, like Munich Reinsurance Co Stock Corp and Calamos Advisors LLC. Some entities were bullish about Thermo Fisher's stock, with TD Cowen retaining a 'Buy' rating despite lowering the price target. However, Stifel Nicolaus issued a pessimistic forecast. Amid these developments, Thermo Fisher was evaluated as a 'moderate buy' by analysts.
